Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Aug 21, 2019 in Colorectal cancer | 0 comments

In a nutshell

This study investigated the role of tumor budding (TB) in predicting the best treatment for stage 2 colon cancer. Researchers suggested that TB could improve the effect of chemotherapy after surgery in these patients.

Some background

Stage 2 colorectal cancer accounts for one-third of patients who undergo curative surgery. Prognostic factors help to decide on the best treatment after colon surgery.

TB consists of the presence of individual cells or small clusters of cells surrounding the tumor. As these cells may remain in the body after surgery, the risk of recurrence (when the cancer comes back) is higher. Prior studies showed that TB can be a good prognostic factor for patients with a high risk of recurrence. This will help to decide the best treatment after surgery for each patient.  However, it is not clear if patients with TB benefit from chemotherapy after surgery.

Methods & findings

This study included 991 patients with stage 2 colon cancer. Off these, 376 patients had light TB, 331 had mild to severe TB and 284 had severe TB.

The 5-year recurrence-free rate (RFR; the percentage of patients without a recurrence 5 years after treatment) was 90.9% for the light group, 85.1% for the mild and 74.4% for the severe group. 

TB and cancer stage significantly impacted the RFR. Both mild and severe groups who received chemotherapy after surgery had a 5% improvement in the 5-year RFR when compared to surgery alone.

The bottom line

This study concluded that TB should be routinely tested and could improve the benefit of chemotherapy after surgery.

The fine print

This study had a limited number of participants. Also, only one chemotherapy drug was used for the patients in this study. Further studies with a bigger population are necessary.

Published By :

Journal of clinical oncology

Date :

Jun 10, 2019

Original Title :

Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial.

click here to get personalized updates